Company news
Longeveron Inc. (NASDAQ:LGVN) news
Longeveron Inc. news releases on 6ix. Latest, Sep 30, 2026: Longeveron to Participate in Three Longevity/Aging Investment Conferences
Press releases & updates
Longeveron to Participate in Three Longevity/Aging Investment Conferences
September 30, 2026
Longeveron to Participate in Three Longevity/Aging Investment Conferences
September 29, 2026
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
September 16, 2026
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
August 19, 2026
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
August 12, 2026
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
August 11, 2026
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
August 3, 2026
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
July 23, 2026
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
July 13, 2026
Longeveron® Appoints Marie Washburn as Chief Financial Officer
July 6, 2026
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
June 9, 2026
Longeveron to Present at BIO International Convention 2026
June 3, 2026
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
May 20, 2026
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
May 13, 2026
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
May 10, 2026
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 8, 2026
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
May 5, 2026
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
April 7, 2026
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
March 16, 2026
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
March 12, 2026
Longeveron Announces Closing of Private Placement of up to $30 Million
March 10, 2026
Longeveron Announces Private Placement of up to $30 Million
March 9, 2026
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
February 25, 2026
Longeveron Appoints Stephen H. Willard as Chief Executive Officer
February 16, 2026
Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
February 13, 2026
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
February 5, 2026
Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells
January 30, 2026
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
January 29, 2026
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
January 26, 2026
Longeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
December 29, 2025
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
December 17, 2025
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
December 3, 2025
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
December 2, 2025
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
December 1, 2025
Longeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
November 19, 2025
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
November 12, 2025
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
November 4, 2025
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
October 27, 2025
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
October 6, 2025
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
October 1, 2025
Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 22, 2025
Longeveron® Announces Key Leadership Updates
September 3, 2025
Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
August 20, 2025
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update
August 13, 2025
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
August 11, 2025
Longeveron Announces Up To $17.5 Million Public Offering
August 8, 2025
Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
August 5, 2025
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
July 21, 2025